



BIOHEART

Media Contact: Carissa Matton
Bioheart, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
Phone: 954.835.1500
cmatton@bioheartinc.com

For Immediate Release

Bioheart Confirms Date and Access for Shareholder Conference Call

Strategic Direction for 2015 and Forward to be Highlighted

Sunrise, FL – January 28, 2015 – Bioheart, Inc., a Florida Corporation (BHRT.OB), an emerging enterprise in the regenerative medicine / cellular therapy industry confirmed today that it will convene a shareholder conference call on February 4th, at 4:30 pm EST to discuss its strategic direction and business plans for 2015 and forward. The conference call will be hosted by Mike Tomas, CEO and will include presentations from management and a question and answer session. Access to the shareholder conference call can be made by phone or through the Internet as follows, but please note that presentation materials will only be available through the web access portal:

<https://attendee.gotowebinar.com/register/3897477713991000577>

After registering, you will receive a confirmation email containing information about joining the webinar.

[View System Requirements](#)

Conference Call Dial In Instructions:

Long distance: +1 (702) 489-0004

Access Code: 835-047-376

“We are looking forward to speaking with you next week and presenting to you our plans for 2015 and beyond,” said Mike Tomas, President & CEO. “We believe that you will find our goals for Bioheart to be both exciting and achievable. While Bioheart is a long-

established venture in the regenerative medicine / cellular therapeutics industry, we believe our strategy propels us into the new generation of thinking on how to build a successful biotechnology company. Again, we look forward to speaking with you next week.”

About Bioheart, Inc.

Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2013, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2014.